Dmitri Bobilev - 04 Jan 2024 Form 4 Insider Report for Fusion Pharmaceuticals Inc.

Role
Chief Medical Officer
Signature
/s/ Maria Stahl as Attorney-in-Fact for Dmitri Bobilev
Issuer symbol
N/A
Transactions as of
04 Jan 2024
Net transactions value
$0
Form type
4
Filing time
05 Jan 2024, 08:46:23 UTC
Previous filing
07 Nov 2022
Next filing
04 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FUSN Stock Option (Right to Buy) Award $0 +151,700 $0.000000 151,700 04 Jan 2024 Common Stock 151,700 $8.44 Direct F1
transaction FUSN Restricted Stock Units Award $0 +91,000 $0.000000 91,000 04 Jan 2024 Common Stock 91,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in 48 equal monthly installments beginning on February 4, 2024.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock of Fusion Pharmaceuticals Inc. for no consideration.
F3 The restricted stock units vest in six equal installments on each of July 4, 2024, January 4, 2025, July 4, 2025, January 4, 2026, July 4, 2026 and January 4, 2027.